Mexico - Delayed Quote MXN

bluebird bio, Inc. (BLUE.MX)

80.00
0.00
(0.00%)
At close: April 21 at 7:41:33 AM CST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BLUE.MX

Recent News: BLUE.MX

View More
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
Business Wire 3 days ago
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
Business Wire 5 days ago
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
Business Wire 10 days ago
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
Business Wire 14 days ago
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
Business Wire last month
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
Business Wire last month
Gene therapy maker bluebird to go private in discounted deal amid cash crunch

Gene therapy maker bluebird to go private in discounted deal amid cash crunch
Reuters 2 months ago
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Business Wire 2 months ago
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?

bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?
Insider Monkey 4 months ago
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire 5 months ago
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Business Wire 5 months ago
View More

Related Tickers

DEX.ST DexTech Medical AB
5.45
-9.17%
 
1CVAC.MI CureVac N.V.
3.4380
+3.74%
 
1GDA.F Zevra Therapeutics, Inc.
7.80
+1.96%
 
8EM.F Editas Medicine, Inc.
1.2720
-5.07%
 
22UA.MU BioNTech SE
86.60
+2.67%
 
ALGEN.PA genOway Société anonyme
3.1800
+1.60%
 
HRTIS.HE Herantis Pharma Oyj
1.4150
-1.05%
 
63E.F Onward Medical N.V.
4.0000
+2.43%
 
BBZA.DE BB Biotech AG
31.20
+0.16%
 
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.3770
-4.80%